Table 2.
Baseline demographic and clinical characteristics of the NUCs discontinuation patients treated by lamivudine, adefovir, entecavir, and telbivudine
| Characteristic | LAM | ADV | ETV | LDT |
|---|---|---|---|---|
| Number. (%) |
15 (22.7) |
42 (63.6) |
7 (10.6) |
2 (3.0) |
| Age (Mean ±SD) - yr |
34.1±13.0 |
35.3±10.6 |
36.1±14.0 |
33.5±10.6 |
| <29 - no. |
4 |
9 |
2 |
1 |
| 30-39 - no. |
8 |
24 |
3 |
0 |
| >39 - no. |
3 |
9 |
2 |
1 |
| Man - no. (%) |
14 (93.3) |
30 (71.4) |
4 (57.1) |
2 (100) |
| ALT [Median (IQR)] - ULN |
2.6 (1.2-3.5) |
2.5 (1.3-6.6) |
4.7 (2.7-14.0) |
9.5 (3.9, 15.0) |
| HBV DNA - log10 IU/mL |
6.3±1.6 |
5.3±1.3 |
5.5±0.8 |
7.0±2.2 |
| HBsAg loss - no. (%) | 2 (100) | 0 | 0 | 0 |
LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.